Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 30,000 shares, a growth of 98.7% from the February 13th total of 15,100 shares. Based on an average trading volume of 362,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 5.4% of the shares of the stock are short sold.

Bluejay Diagnostics Price Performance

Shares of BJDX opened at $4.04 on Friday. The company has a market capitalization of $2.23 million, a P/E ratio of 0.00 and a beta of 0.38. Bluejay Diagnostics has a one year low of $3.03 and a one year high of $349.56. The business’s 50 day simple moving average is $3.75 and its 200-day simple moving average is $4.85.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bluejay Diagnostics stock. Anson Funds Management LP increased its stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 319,280 shares of the company’s stock after purchasing an additional 249,770 shares during the period. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.